Extracellular matrix biomarker, fibulin-1, is closely related to NT-proBNP and soluble urokinase plasminogen activator receptor in patients with aortic valve stenosis (the SEAS study).

<h4>Background</h4>Fibulin-1, a circulating extracellular matrix glycoprotein, has been associated with arterial disease and elevated N-terminal prohormone B-type natriuretic peptide (NT-proBNP) in diabetes. Soluble urokinase plasminogen activator receptor (suPAR), a marker of inflammati...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ruan Kruger, Lars M Rasmussen, William S Argraves, Jesper Eugen-Olsen, Olav W Nielsen, Adam Blyme, Ronnie Willenheimer, Kristian Wachtell, Michael H Olsen
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/62112d6de1df4a758af9fb25e83c1bd1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:62112d6de1df4a758af9fb25e83c1bd1
record_format	dspace
spelling	oai:doaj.org-article:62112d6de1df4a758af9fb25e83c1bd12021-11-25T06:08:49ZExtracellular matrix biomarker, fibulin-1, is closely related to NT-proBNP and soluble urokinase plasminogen activator receptor in patients with aortic valve stenosis (the SEAS study).1932-620310.1371/journal.pone.0101522https://doaj.org/article/62112d6de1df4a758af9fb25e83c1bd12014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25014213/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Fibulin-1, a circulating extracellular matrix glycoprotein, has been associated with arterial disease and elevated N-terminal prohormone B-type natriuretic peptide (NT-proBNP) in diabetes. Soluble urokinase plasminogen activator receptor (suPAR), a marker of inflammation, has been associated with subclinical atherosclerosis. Therefore, we aimed to explore the interplay between these biomarkers and mild to moderate aortic valve stenosis (AS).<h4>Methods</h4>In 374 patients with mild to moderate AS, we investigated the relationship of fibulin-1 with NT-proBNP, levels of suPAR and the degree of AS at baseline and after one and four years of treatment with Simvastatin 40 mg and Ezetimibe 10 mg or placebo.<h4>Results</h4>During treatment, fibulin-1 became more closely associated with NT-proBNP (βyear0 = 0.10, p = 0.08, βyear1 = 0.16, p = 0.005, βyear4 = 0.22, p<0.001) and suPAR (βyear0 = 0.05, p = 0.34, βyear1 = 0.16, p = 0.006, βyear4 = 0.13, p = 0.03) at the expense of the association to aortic valve area index (AVAI) (βyear0 = -0.14, p = 0.005, βyear1 = -0.08, p = 0.11, βyear4 = -0.06, p = 0.22) independently of age, gender, creatinine, and serum aspartate aminotransferase (Adj.Ryear02 = 0.19, Adj.Ryear12 = 0.22, Adj.Ryear42 = 0.27). Fibulin-1 was unrelated to aortic regurgitation, left ventricular mass, and ejection fraction. In patients with baseline AVAI<0.58 cm2/m2 (median value), fibulin-1 was more closely associated to NT-proBNP (βyear0 = 0.25, βyear1 = 0.21, βyear4 = 0.22, all p<0.01), and suPAR (βyear0 = 0.09, p = 0.26, βyear1 = 0.23, βyear4 = 0.21, both p<0.01) independently of age, gender, AST and treatment allocation.<h4>Conclusions</h4>Increased levels of fibulin-1 were independently associated with higher levels of suPAR and NT-proBNP especially in patients with lower AVAI, suggesting that fibulin-1 may be an early marker of AS as well as cardiac fibrosis secondarily to elevated left ventricular hemodynamic load.Ruan KrugerLars M RasmussenWilliam S ArgravesJesper Eugen-OlsenOlav W NielsenAdam BlymeRonnie WillenheimerKristian WachtellMichael H OlsenPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 7, p e101522 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ruan Kruger Lars M Rasmussen William S Argraves Jesper Eugen-Olsen Olav W Nielsen Adam Blyme Ronnie Willenheimer Kristian Wachtell Michael H Olsen Extracellular matrix biomarker, fibulin-1, is closely related to NT-proBNP and soluble urokinase plasminogen activator receptor in patients with aortic valve stenosis (the SEAS study).
description	<h4>Background</h4>Fibulin-1, a circulating extracellular matrix glycoprotein, has been associated with arterial disease and elevated N-terminal prohormone B-type natriuretic peptide (NT-proBNP) in diabetes. Soluble urokinase plasminogen activator receptor (suPAR), a marker of inflammation, has been associated with subclinical atherosclerosis. Therefore, we aimed to explore the interplay between these biomarkers and mild to moderate aortic valve stenosis (AS).<h4>Methods</h4>In 374 patients with mild to moderate AS, we investigated the relationship of fibulin-1 with NT-proBNP, levels of suPAR and the degree of AS at baseline and after one and four years of treatment with Simvastatin 40 mg and Ezetimibe 10 mg or placebo.<h4>Results</h4>During treatment, fibulin-1 became more closely associated with NT-proBNP (βyear0 = 0.10, p = 0.08, βyear1 = 0.16, p = 0.005, βyear4 = 0.22, p<0.001) and suPAR (βyear0 = 0.05, p = 0.34, βyear1 = 0.16, p = 0.006, βyear4 = 0.13, p = 0.03) at the expense of the association to aortic valve area index (AVAI) (βyear0 = -0.14, p = 0.005, βyear1 = -0.08, p = 0.11, βyear4 = -0.06, p = 0.22) independently of age, gender, creatinine, and serum aspartate aminotransferase (Adj.Ryear02 = 0.19, Adj.Ryear12 = 0.22, Adj.Ryear42 = 0.27). Fibulin-1 was unrelated to aortic regurgitation, left ventricular mass, and ejection fraction. In patients with baseline AVAI<0.58 cm2/m2 (median value), fibulin-1 was more closely associated to NT-proBNP (βyear0 = 0.25, βyear1 = 0.21, βyear4 = 0.22, all p<0.01), and suPAR (βyear0 = 0.09, p = 0.26, βyear1 = 0.23, βyear4 = 0.21, both p<0.01) independently of age, gender, AST and treatment allocation.<h4>Conclusions</h4>Increased levels of fibulin-1 were independently associated with higher levels of suPAR and NT-proBNP especially in patients with lower AVAI, suggesting that fibulin-1 may be an early marker of AS as well as cardiac fibrosis secondarily to elevated left ventricular hemodynamic load.
format	article
author	Ruan Kruger Lars M Rasmussen William S Argraves Jesper Eugen-Olsen Olav W Nielsen Adam Blyme Ronnie Willenheimer Kristian Wachtell Michael H Olsen
author_facet	Ruan Kruger Lars M Rasmussen William S Argraves Jesper Eugen-Olsen Olav W Nielsen Adam Blyme Ronnie Willenheimer Kristian Wachtell Michael H Olsen
author_sort	Ruan Kruger
title	Extracellular matrix biomarker, fibulin-1, is closely related to NT-proBNP and soluble urokinase plasminogen activator receptor in patients with aortic valve stenosis (the SEAS study).
title_short	Extracellular matrix biomarker, fibulin-1, is closely related to NT-proBNP and soluble urokinase plasminogen activator receptor in patients with aortic valve stenosis (the SEAS study).
title_full	Extracellular matrix biomarker, fibulin-1, is closely related to NT-proBNP and soluble urokinase plasminogen activator receptor in patients with aortic valve stenosis (the SEAS study).
title_fullStr	Extracellular matrix biomarker, fibulin-1, is closely related to NT-proBNP and soluble urokinase plasminogen activator receptor in patients with aortic valve stenosis (the SEAS study).
title_full_unstemmed	Extracellular matrix biomarker, fibulin-1, is closely related to NT-proBNP and soluble urokinase plasminogen activator receptor in patients with aortic valve stenosis (the SEAS study).
title_sort	extracellular matrix biomarker, fibulin-1, is closely related to nt-probnp and soluble urokinase plasminogen activator receptor in patients with aortic valve stenosis (the seas study).
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/62112d6de1df4a758af9fb25e83c1bd1
work_keys_str_mv	AT ruankruger extracellularmatrixbiomarkerfibulin1iscloselyrelatedtontprobnpandsolubleurokinaseplasminogenactivatorreceptorinpatientswithaorticvalvestenosistheseasstudy AT larsmrasmussen extracellularmatrixbiomarkerfibulin1iscloselyrelatedtontprobnpandsolubleurokinaseplasminogenactivatorreceptorinpatientswithaorticvalvestenosistheseasstudy AT williamsargraves extracellularmatrixbiomarkerfibulin1iscloselyrelatedtontprobnpandsolubleurokinaseplasminogenactivatorreceptorinpatientswithaorticvalvestenosistheseasstudy AT jespereugenolsen extracellularmatrixbiomarkerfibulin1iscloselyrelatedtontprobnpandsolubleurokinaseplasminogenactivatorreceptorinpatientswithaorticvalvestenosistheseasstudy AT olavwnielsen extracellularmatrixbiomarkerfibulin1iscloselyrelatedtontprobnpandsolubleurokinaseplasminogenactivatorreceptorinpatientswithaorticvalvestenosistheseasstudy AT adamblyme extracellularmatrixbiomarkerfibulin1iscloselyrelatedtontprobnpandsolubleurokinaseplasminogenactivatorreceptorinpatientswithaorticvalvestenosistheseasstudy AT ronniewillenheimer extracellularmatrixbiomarkerfibulin1iscloselyrelatedtontprobnpandsolubleurokinaseplasminogenactivatorreceptorinpatientswithaorticvalvestenosistheseasstudy AT kristianwachtell extracellularmatrixbiomarkerfibulin1iscloselyrelatedtontprobnpandsolubleurokinaseplasminogenactivatorreceptorinpatientswithaorticvalvestenosistheseasstudy AT michaelholsen extracellularmatrixbiomarkerfibulin1iscloselyrelatedtontprobnpandsolubleurokinaseplasminogenactivatorreceptorinpatientswithaorticvalvestenosistheseasstudy
_version_	1718414104983502848

Extracellular matrix biomarker, fibulin-1, is closely related to NT-proBNP and soluble urokinase plasminogen activator receptor in patients with aortic valve stenosis (the SEAS study).

Ejemplares similares